| Time |
Session Title |
| 7:00 a.m. |
Registration Open & Breakfast Served |
Session 1: Fundamentals (100)
Moderators: Guy Johnson, MD, University of Washington; David S. Wang, MD, FSIR, Stanford Health Care |
| 8:00 - 8:15 a.m. |
What Do I Need to Know as an IR on Oncology
Daniel B. Brown, MD, FSIR, Vanderbilt University Medical Center |
| 8:15 - 8:30 a.m. |
Dosimetric Principles of Glass and Resin Microspheres
S. Cheenu, Kappadath, PhD, FAAPM, University of Texas MD Anderson Cancer Center |
| 8:30 - 8:45 a.m. |
Absorbed Dose and Specific Activity
Marnix Lam, MD, PhD, University Medical Center Utrecht |
| 8:45 - 9:00 a.m. |
Optimizing Patient Selection: HCC vs Metastatic Disease
Christopher D. Malone, MD, Mallinckrodt Institute of Radiology at Washington University School of Medicine |
| 9:00 - 9:15 a.m. |
Patient Management: Clinical and Imaging
Nadine Abi-Jaoudeh, MD, University of California Irvine |
| 9:15 - 9:45 a.m. |
Discussion
All session faculty |
| 9:45 - 10:15 a.m. |
Break & Exhibits |
Session 2: Data Deep Dive: Early Stage HCC (100-200)
Moderators: Edward Kim, MD, FSIR, Mount Sinai Health Systems; Nima Kokabi, MD, University of North Carolina |
| 10:15 - 10:30 a.m. |
Why I Choose Glass Microspheres for RadSeg
Siddharth Padia, MD, UCLA Santa Monica |
| 10:30 - 10:45 a.m. |
Why I Choose Resin Microspheres for RadSeg
Ammar Sarwar, MD, FSIR, Beth Israel Deacconess Medical Center/Harvard Medical School |
| 10:45 - 11:00 a.m. |
Is TARE Superior in Bridging/Downstaging Patients?
Evan Lehrman, MD, FSIR, UCSF |
| 11:00 - 11:15 a.m. |
Role of Radiation Lobectomy in HCC
Kirema Garcia-Reyes,MD, Icahn School of Medicine at Mount Sinai |
| 11:15 - 11:45 a.m. |
Discussion
All session faculty |
| 11:45 a.m. - 12:45 p.m. |
Lunch & Exhibits |
Session 3: Data Deep Dive: Intermediate & Advanced HCC (100-200)
Moderator: Edward Kim, MD, FSIR, Mount Sinai Health Systems; Christopher D. Malone, MD, Mallinckrodt Institute of Radiology at Washington University School of Medicine |
| 12:45 - 1:00 p.m. |
TARE or TACE in Intermediate Stage HCC?
Ghassan El-Haddad, MD, Moffitt Cancer Center |
| 1:00 - 1:15 p.m. |
Expanding Role for Systemic Therapy in HCC: Moving to Intermediate Stage and Combinations
Lingling Du, MD, Ochsner MD Anderson Cancer Center |
| 1:15 - 1:30 p.m. |
Is TARE Still Relevant in Advanced Stage HCC?
Robert J. Lewandowski, MD, FSIR, Northwestern Medicine |
| 1:30 - 1:45 p.m. |
Checkpoint Inhibitor Review for Advanced Stage: Potential for Combination?
Lingling Du, MD, Ochsner MD Anderson Medical Center |
| 1:45 - 2:15 p.m. |
Discussion
All session faculty |
| 2:15 - 2:30 p.m. |
Break |
Session 4: Everything Else (100-200)
Moderators: Daniel B. Brown, MD, FSIR, Vanderbilt University Medical Center, and William Rilling, MD, FSIR, Medical College of Wisconsin |
| 2:30 - 2:45 p.m. |
mCRC: When to Use TARE Amongst Systemic Therapy
Daniel B. Brown, MD, FSIR, Vanderbilt University Medical Center |
| 2:45 - 3:00 p.m. |
Cholangiocarcinoma: TARE/SBRT or Systemic
William Rilling, MD, FSIR, Medical College of Wisconsin |
| 3:00 - 3:15 p.m. |
mNET: Is TARE Making a Comeback?
Ghassan El-Haddad, MD, Moffitt Cancer Center |
| 3:15 - 3:30 p.m. |
Current Status of Data and Ongoing Trials in Glass Microspheres
William Rilling, MD, FSIR, Medical College of Wisconsin |
| 3:30 - 3:45 p.m. |
Current Status of Data and Ongoing Trials in Resin Microspheres
Thomas Helmberger, MD, PhD, Munich Klinik Bogenhausen |
| 3:45 - 4:00 p.m. |
Current Status of Data and Ongoing Trials in Radio-opaque Glass Microspheres
Nadine Abi-Jaoudeh, MD, University of California Irvine |
| 4:00 - 4:30 p.m. |
Discussion
All session faculty |
| 4:30 - 5:30 p.m. |
Happy Hour Networking & Exhibits |